Ascentage Pharma Group Internat AAPG
15.07 USD +1.59 (+11.75%)
At closeNov 4, 2026, 4:00 PM EST
15.07 0.00 0.00%
After hours · Nov 4, 4:00 PM ET
14.44 Day range 15.50
13.46 52-week range 34.50
- YTD
- -42.57%
- 1 year
- -54.68%
Analyst view
Price target (mean) 44.50 +195.3% upside
Now 15.07
- Target (low)
- 33.00
- Target (mean)
- 44.50
- Target (high)
- 55.00
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy3
- Buy8
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 8
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.56044 | -0.62 – -0.50087 | 0.00 | 0.0% | 178.31M | 0.0% | 2 |
| Next quarter | -0.50544 | -0.51 – -0.50087 | 0.00 | 0.0% | 199.41M | 0.0% | 2 |
| Current year | -1.18 | -2.38 – -0.57 | -2.00 | +41.1% | 677.61M | +18.0% | 6 |
| Next year | -0.64702 | -2.05 – 0.045 | -1.18 | +45.1% | 1.44B | +111.9% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | William Blair | Initiated | — | Outperform |
| Oct 14, 2026 | Citigroup | Initiated | — | Buy |
| Oct 13, 2026 | Citizens | Initiated | — | Market Outperform |
| Oct 8, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 21, 2026 | BTIG | Reiterated | Buy | Buy |
| Jun 15, 2026 | BTIG | Reiterated | Buy | Buy |
| Jun 10, 2026 | B. Riley Securities | Initiated | — | Buy |
| Apr 13, 2026 | BTIG | Reiterated | Buy | Buy |
| Mar 26, 2026 | BTIG | Reiterated | Buy | Buy |
| Dec 4, 2025 | Oppenheimer | Initiated | — | Outperform |
| Nov 24, 2025 | Truist Securities | Initiated | — | Buy |
| Nov 10, 2025 | BTIG | Initiated | — | Buy |
| Nov 5, 2025 | Piper Sandler | Initiated | — | Overweight |
| Mar 27, 2025 | JP Morgan | Initiated | — | Overweight |